On the morning of Aug. 9, a patient and resident in Hengqin surnamed Luo received the first injection of the imported drug, Inclisiran, at the Hengqin branch of the Zhuhai People’s Hospital.
This new drug has been introduced under the “Medicine and Equipment Connect” policy, which enables the import of medicines and equipment that are already on the market and used in public hospitals in Hong Kong and Macau, and are urgently needed for clinical use in the mainland.
Inclisiran, as a prefilled injection, is the world’s first small interfering RNA lipid-lowering drug for cardiovascular disease. It is mostly used in patients with hyperlipidemia, and those who are unable to tolerate statins or those with familial hypercholesterolemia.
In February, the Zhuhai People’s Hospital (Hengqin Branch) was listed in the second batch of designated medical institutions in the Guangdong-Hong Kong-Macau Greater Bay Area for “Medicine and Equipment Connect”.
The hospital is expected to introduce more international medicine and devices to serve the local residents, providing clinicians and patients in Hengqin with more choices in treatment. MDT/GDTODAY
